Palifosfamide is primarily used in the field of oncology as a chemotherapeutic agent. It is specifically designed to treat various types of cancer by targeting and destroying cancer cells. The compound works by alkylating DNA, which disrupts the cancer cells' ability to replicate and ultimately leads to their death. This mechanism makes it effective in slowing or stopping the progression of malignancies.

One of the key applications of Palifosfamide is in the treatment of soft tissue sarcoma, a type of cancer that arises from connective tissues. It has shown promise in clinical trials for improving outcomes in patients with this condition. Additionally, it is being explored for use in other cancers, including non-small cell lung cancer, where traditional treatments may be less effective or have significant side effects.

Palifosfamide is often considered for patients who have not responded well to other forms of chemotherapy or who are seeking alternative treatment options. Its formulation aims to enhance stability and reduce toxicity compared to its parent compound, ifosfamide, making it a potentially safer option for long-term therapy. Ongoing research continues to evaluate its efficacy and safety in broader cancer populations.